122 related articles for article (PubMed ID: 1503488)
21. [Comparative study on vindesine plus cisplatin treatment of advanced non-small cell lung cancer--three divided doses (35 mg/m2, day 1, 8, 15) and single dose (80 mg/m2, day 1) of cisplatin. Chiba Lung Cancer Study Group].
Nagao K; Fujisawa T; Miyamoto T; Kikuchi N; Takizawa H; Satoh K; Yamagishi F; Yamaguchi T; Mizutani F; Nakano K
Gan To Kagaku Ryoho; 1991 Mar; 18(3):425-30. PubMed ID: 1848421
[TBL] [Abstract][Full Text] [Related]
22. [Cisplatin (platidiam) and the prospects for using complex platinum compounds in the clinical chemotherapy of malignant tumors].
Gorbunova VA
Vopr Onkol; 1989; 35(3):325-30. PubMed ID: 2705315
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group.
Akaza H; Togashi M; Nishio Y; Miki T; Kotake T; Matsumura Y; Yoshida O; Aso Y
Cancer Chemother Pharmacol; 1992; 31(3):187-92. PubMed ID: 1334448
[TBL] [Abstract][Full Text] [Related]
24. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
25. Hearing loss--risk factor for cisplatin ototoxicity? Observations.
Durrant JD; Rodgers G; Myers EN; Johnson JT
Am J Otol; 1990 Sep; 11(5):375-7. PubMed ID: 2240186
[TBL] [Abstract][Full Text] [Related]
26. Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin.
Hecquet B; Caty A; Fournier C; Lefebvre JL; Adenis L
Bull Cancer; 1987; 74(4):433-6. PubMed ID: 3311237
[TBL] [Abstract][Full Text] [Related]
27. [Phase II study on cis-diamminedichloroplatinum (II) by a collaborative study].
Gan To Kagaku Ryoho; 1982 Jan; 9(1):46-54. PubMed ID: 6892191
[TBL] [Abstract][Full Text] [Related]
28. Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin.
Koshiyama M; Kinezaki M; Uchida T; Sumitomo M
Anticancer Res; 2005; 25(6C):4499-502. PubMed ID: 16334133
[TBL] [Abstract][Full Text] [Related]
29. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of carboplatin in non-small cell lung cancer.
Olver IN; Donehower RC; Van Echo DA; Ettinger DS; Aisner J
Cancer Treat Rep; 1986 Mar; 70(3):421-2. PubMed ID: 3513947
[No Abstract] [Full Text] [Related]
31. Phase II study of high-dose cis-dichlorodiammineplatinum(II) in the treatment of non-small cell lung cancer.
Casper ES; Gralla RJ; Kelsen DP; Cvitkovic E; Golbey RB
Cancer Treat Rep; 1979; 63(11-12):2107-9. PubMed ID: 575068
[No Abstract] [Full Text] [Related]
32. Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study.
Al-Sarraf M; Metch B; Kish J; Ensley J; Rinehart JJ; Schuller DE; Coltman CA
Cancer Treat Rep; 1987; 71(7-8):723-6. PubMed ID: 3300967
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
[TBL] [Abstract][Full Text] [Related]
34. [Prospects for using platinum coordination compounds possessing antitumor activity].
Sidorik EP; Burlaka AP; Sirdorik OA; Korchevaia LM
Eksp Onkol; 1984; 6(6):6-12. PubMed ID: 6396067
[TBL] [Abstract][Full Text] [Related]
35. Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer.
Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Sasaki Y; Fujita J; Futami H
Cancer Treat Rep; 1985 Sep; 69(9):945-51. PubMed ID: 2992785
[TBL] [Abstract][Full Text] [Related]
36. Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer.
Schmidinger M; Budinsky AC; Wenzel C; Piribauer M; Brix R; Kautzky M; Oder W; Locker GJ; Zielinski CC; Steger GG
Wien Klin Wochenschr; 2000 Jul; 112(14):617-23. PubMed ID: 11008323
[TBL] [Abstract][Full Text] [Related]
37. [Phase II study of a three-drug combination of ifosfamide, cisplatin and vindesine in non-small-cell lung cancer].
Ohnoshi T; Hiraki S; Ueoka H; Tamura T; Kawahara S; Yonei T; Yamashita H; Ishii J; Tamai M; Egawa T
Gan To Kagaku Ryoho; 1988 Jan; 15(1):115-9. PubMed ID: 2827585
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of carboplatin in metastatic transitional cell carcinoma of the bladder (a report of the Medical Research Council Working Party on Urological Cancer, Subgroup in Advanced Bladder Cancer).
Eur J Cancer Clin Oncol; 1987 Apr; 23(4):375-7. PubMed ID: 3301367
[TBL] [Abstract][Full Text] [Related]
39. [A randomized trial comparing vindesine plus cisplatin with mitomycin C, vindesine plus cisplatin in patients with advanced non-small cell lung cancer].
Fujii M; Kiura K; Okabe K; Toki H; Kimura M
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2676-81. PubMed ID: 2820312
[TBL] [Abstract][Full Text] [Related]
40. Decreased hearing after combined modality therapy for head and neck cancer.
Pearson SE; Meyer AC; Adams GL; Ondrey FG
Am J Otolaryngol; 2006; 27(2):76-80. PubMed ID: 16500467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
